The agency has scheduled a hearing and comment period on initiative for faster evaluation of priority therapies.
The U.S. Food and Drug Administration (FDA) recently announced a Federal Register notice seeking public comment on its Commissioner’s National Priority Voucher pilot program and scheduled a public hearing for June 12. The agency said the process will gather feedback on eligibility criteria, review procedures, sponsor responsibilities, and implementation of the expedited pathway, which was launched in June 2025 to address selected public health priorities while maintaining existing regulatory standards.
The FDA explained that the program offers qualifying applicants expedited review of a single drug or biologic application and enhanced regulatory engagement. The agency reported awarding 18 vouchers and granting four approvals to date, including oncology products reviewed within weeks of filing.
“As a clinician who has been frustrated at the bedside by a lack of available treatment options, I’m excited about the potential of this program’s future following a very successful first year. As with all of our new initiatives, we are seeking input on how we can better meet the needs of the American people,” said FDA Commissioner Marty Makary.
The agency is requesting stakeholder input as it evaluates the program’s future, with written comments accepted through June 27 and participation available in person or virtually.
As the Lord Leads, Pray with Us…
- For FDA Commissioner Makary to be prudent as he advocates for increased access to therapies.
- For officials of the FDA as they evaluate expedited review processes for medical products.
- For FDA’s Office of the Commissioner, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, and Oncology Center of Excellence as they conduct the scientific review.
Sources: Food and Drug Administration
